Innovent Biologics (1801) Financial Statements

26 Followers

Innovent Biologics Financial Overview

Innovent Biologics's market cap is currently HK$139.58B. The company's EPS TTM is HK$0.4979; its P/E ratio is -762.50; Innovent Biologics is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is HK$0.86. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	¥ 13.04B	¥ 9.42B	¥ 6.21B	¥ 4.56B	¥ 4.27B
Gross Profit	¥ 10.00B	¥ 7.91B	¥ 4.40B	¥ 3.63B	¥ 3.70B
Operating Income	¥ 733.62M	¥ -755.87M	¥ -1.68B	¥ -3.12B	¥ -2.70B
EBITDA	¥ 1.31B	¥ -480.28M	¥ -660.68M	¥ -1.75B	¥ -2.37B
Net Income	¥ 813.57M	¥ -94.63M	¥ -1.03B	¥ -2.18B	¥ -2.73B
Balance Sheet
Cash & Short-Term Investments	¥ 18.24B	¥ 7.88B	¥ 10.97B	¥ 9.17B	¥ 9.02B
Total Assets	¥ 37.36B	¥ 21.60B	¥ 20.63B	¥ 17.59B	¥ 16.24B
Total Debt	¥ 2.82B	¥ 2.83B	¥ 3.62B	¥ 3.23B	¥ 2.50B
Net Debt	¥ -14.54B	¥ -4.68B	¥ -6.43B	¥ 2.21B	¥ 1.14B
Total Liabilities	¥ 17.20B	¥ 8.48B	¥ 8.10B	¥ 6.86B	¥ 5.91B
Stockholders' Equity	¥ 19.36B	¥ 13.12B	¥ 12.53B	¥ 10.73B	¥ 10.33B
Cash Flow
Free Cash Flow	¥ 9.32B	¥ -418.39M	¥ -1.24B	¥ -3.30B	¥ -3.87B
Operating Cash Flow	¥ 10.00B	¥ 1.29B	¥ 147.81M	¥ -1.92B	¥ -2.02B
Investing Cash Flow	¥ -6.51B	¥ -1.17B	¥ -998.66M	¥ -1.44B	¥ -2.70B
Financing Cash Flow	¥ 4.73B	¥ -606.63M	¥ 2.59B	¥ 2.89B	¥ 5.00B

Currency in CNY

Innovent Biologics Earnings and Revenue History

Income Statement >

Innovent Biologics Debt to Assets

Balance Sheet >

Innovent Biologics Cash Flow

Cash Flow >

Innovent Biologics Forecast EPS vs Actual EPS

Earnings >